Leap therapeutics presents updated positive data from the distinguish study of dkn-01 plus tislelizumab at the esmo congress

Cambridge, mass., sept. 16, 2021 /prnewswire/ -- leap therapeutics, inc. (nasdaq:lptx), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced the presentation of updated positive data from the first-line cohort of the distinguish study, a phase 2a clinical trial evaluating leap's anti-dickkopf-1 (dkk1) antibody, dkn-01, in combination with tislelizumab, beigene ltd.
LPTX Ratings Summary
LPTX Quant Ranking